olmesartan medoxomil + hydrochlorothiazide + amlodipine + hydralazine if necessary to control blood pressure + atenolol+ hydrochlorothiazide + amlodipine + hydralazine if necessary to control blood pressure
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Hypertension
Conditions
Hypertension
Trial Timeline
Nov 1, 2002 → Jul 1, 2005
NCT ID
NCT00772499About olmesartan medoxomil + hydrochlorothiazide + amlodipine + hydralazine if necessary to control blood pressure + atenolol+ hydrochlorothiazide + amlodipine + hydralazine if necessary to control blood pressure
olmesartan medoxomil + hydrochlorothiazide + amlodipine + hydralazine if necessary to control blood pressure + atenolol+ hydrochlorothiazide + amlodipine + hydralazine if necessary to control blood pressure is a approved stage product being developed by Daiichi Sankyo for Hypertension. The current trial status is completed. This product is registered under clinical trial identifier NCT00772499. Target conditions include Hypertension.
What happened to similar drugs?
20 of 20 similar drugs in Hypertension were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00772499 | Approved | Completed |
Competing Products
20 competing products in Hypertension